Correction to: High rates of Cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients

Collaborators, Affiliations

Therapeutic Drug Monitoring study group:
Arnim Geise, Golo-Sung Haarmeyer, Matthias Baumgärtel, Jens Nentwich, Axel von Fragstein, Anke Jensen

¹ Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
² Intensive Care Unit, Department of Medicine 1, University Hospital Carl Gustav Carus, TU, Dresden, Dresden, Germany.
³ Institute for Biomedical and Pharmaceutical Research, Nuremberg-Heroldsberg, Germany.
⁴ Study Program in Human Medicine, Paracelsus Medical University, Nuremberg, Germany.
⁵ Institute of Pharmacology, West German Heart and Vascular Centre, University of Duisburg-Essen, Essen, Germany.
⁶ Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany. ralph.bertram@klinikum-nuernberg.de.
⁷ Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany. joerg.steinmann@klinikum-nuernberg.de.

^# Contributed equally.

Published Erratum

Hans Theodor Naumann et al. Crit Care. 2025.

. 2025 Aug 22;29(1):380.

doi: 10.1186/s13054-025-05583-5.

Therapeutic Drug Monitoring study group:
Arnim Geise, Golo-Sung Haarmeyer, Matthias Baumgärtel, Jens Nentwich, Axel von Fragstein, Anke Jensen

¹ Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
² Intensive Care Unit, Department of Medicine 1, University Hospital Carl Gustav Carus, TU, Dresden, Dresden, Germany.
³ Institute for Biomedical and Pharmaceutical Research, Nuremberg-Heroldsberg, Germany.
⁴ Study Program in Human Medicine, Paracelsus Medical University, Nuremberg, Germany.
⁵ Institute of Pharmacology, West German Heart and Vascular Centre, University of Duisburg-Essen, Essen, Germany.
⁶ Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany. ralph.bertram@klinikum-nuernberg.de.
⁷ Institute of Clinical Microbiology, Infectious Diseases and Infection Control, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany. joerg.steinmann@klinikum-nuernberg.de.

^# Contributed equally.

No abstract available

Erratum for

High rates of cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients.
Naumann HT, Höhl R, Kinzig M, Salat S, Bartsch V, Sörgel F, Bertram R, Steinmann J; Therapeutic Drug Monitoring study group. Naumann HT, et al. Crit Care. 2024 Dec 30;28(1):438. doi: 10.1186/s13054-024-05214-5. Crit Care. 2024. PMID: 39736685 Free PMC article. No abstract available.

1. Naumann HT, Höhl R, Kinzig M, et al. High rates of Cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients. Crit Care. 2024;28:438. 10.1186/s13054-024-05214-5. - PMC - PubMed